uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Systemic therapy of aggressive fibromatosis in children and adolescents: Report of the Cooperative Weichteilsarkom Studiengruppe (CWS)
Klinikum Stuttgart Olgahosp, Stuttgart Canc Ctr, Zentrum Kinder Jugend & Frauenmed, Pediat Oncol Hematol & Immunol 5, Stuttgart, Germany..
Univ Childrens Hosp Marburg, Dept Pediat Surg, Marburg, Germany..
Klinikum Stuttgart Olgahosp, Inst Radiol, Zentrum Kinder Jugend & Frauenmed, Stuttgart, Germany..
Univ Kiel, Inst Paidopathol, Kiel, Germany..
Vise andre og tillknytning
2018 (engelsk)Inngår i: Pediatric Blood & Cancer, ISSN 1545-5009, E-ISSN 1545-5017, Vol. 65, nr 5, artikkel-id e26943Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background

Treatment algorithms for patients with aggressive fibromatosis (AF) are challenging. There are limited data available about the use of systemic therapy (ST) in pediatric patients with AF.

Methods

Patient-, tumor-, and treatment-related factors of 90 children and adolescents with AF treated on multiple prospective trials of the Cooperative Weichteilsarkom Studiengruppe (1981-2015) were analyzed with focus on response and outcome of ST.

Results

Median age was 9.48 years (0.02-18.05). Primary resection was performed in 54 patients and ST was administered in 29 of 54 patients because of disease progression or relapse. In 35 patients, ST was the initial treatment modality. A secondary resection was performed in 21 of 35 patients after ST. A total of 64 patients received ST, mainly methotrexate and vinblastine (40%) with a median duration of 380 days. The most frequent radiological response to ST was stable disease at 3 months (39%) and partial response at 6 months (53%). Radiotherapy was administered to 15 of 90 patients. One patient remained on observation only. The 5-year overall survival was 100% and the 5-year event-free survival (EFS) was 44%. Patients who had a primary resection showed a 5-year EFS of 35% versus 59% in patients who had received primary ST (P=0.08). Functional deficiencies as long-term sequelae following resection occurred in 11 patients. At a median follow-up of 5.05 years (0.25-14.88), complete remission was achieved in 51 patients and partial remission in 28 patients.

Conclusions

ST seems appropriate if a primary complete resection is not feasible and at relapse/progression after resection.

sted, utgiver, år, opplag, sider
2018. Vol. 65, nr 5, artikkel-id e26943
Emneord [en]
aggressive fibromatosis, children and adolescents, CWS Group, systemic therapy
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-351621DOI: 10.1002/pbc.26943ISI: 000428457100013PubMedID: 29316163OAI: oai:DiVA.org:uu-351621DiVA, id: diva2:1217534
Tilgjengelig fra: 2018-06-13 Laget: 2018-06-13 Sist oppdatert: 2018-06-13bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Ljungman, Gustaf

Søk i DiVA

Av forfatter/redaktør
Ljungman, Gustaf
Av organisasjonen
I samme tidsskrift
Pediatric Blood & Cancer

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 25 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf